Heavy Traffic: Targeting Diseases through Chemokine Receptor Antagonism
Tuesday April 07, 2020
8:00 am
-
10:00 am
Eastern Time (ET)
Room 16 A
MP
Chair :
Stephanie Davis
National Institutes of Health
Sudarshan Rajagopal
Duke University
Chemotactic cytokine (chemokine) receptors are G protein-coupled receptors best known for their role in promoting cell migration by responding to chemokines produced at sites of infection. Although the chemokine/receptor axis is important for normal immune function and wound healing, abnormal chemokine signaling is associated with numerous inflammmatory diseases. The objective of this symposium is to show how understanding the function and signaling pathways activated by chemokine receptors in order to develop better strategies for treating conditions such as cancer, HIV infection, Parkinson's Disease, and cardiovascular disease.
Speakers
Sudarshan Rajagopal
- Duke University
Biasing CXCR3 to Modulate the Inflammatory Response
Tracy Handel
- University of California, San Diego
Structure and Signaling Mechanisms of G Protein-Coupled vs. Atypical Chemokine Receptors
Adriano Marchese
- Medical College of Wisconsin
Targeting Chemokine Receptor CXCR4 Abundance in Cancer
S. Sakura Minami
- Alkahest
A Small Molecule Antagonist of CCR3 for the Treatment of Age-related Disorders of the Nervous System
Mostafa Khater
- Medical College of Georgia - Augusta University
G protein βγ Translocation to the Golgi Activates the Mitogen-activated Protein Kinases via Phosphoinositide 3-kinase γ
Desislava Nesheva
- University of Nottingham
Using NanoBit Complementation and TR FRET to Study the Mechanism of Action of Small-molecule
Modulators of CXCR2